|
Dr. Lau is a successful pharmaceutical executive who has had extensive experience in both scientific and business management. As Chairman, President and CEO of Ribapharm, he launched the second largest biotech IPO in history ($300 million). During his tenure at Ribapharm he met or exceeded Wall Street expectations every quarter. Prior to Ribapharm, Dr. Lau served as the Head of Worldwide Research and Development for ICN Pharmaceuticals. He played a key role in raising $525 million in convertible bonds that facilitated the restructuring of ICN and the partial spin-off of Ribapharm. In his leadership role at ICN and Ribapharm, Dr. Lau established a number of strategic partnerships including key business agreements with Hoffman La-Roche, Anadys, Schering-Plough and Metabasis.
As Senior Director of Antiviral Therapy at Schering-Plough from 1997-2000, Dr. Lau played a significant role in the FDA approval of Ribavirin/Interferon and Pegylated Interferon alpha-2b. He has more that 250 publications in peer reviewed scientific journals. Dr. Lau was a Principal at Roth Capital Management in San Diego and is currently a special advisor to Novartis. | 